Eli Lilly to Seek US Approval for Taltz as Treatment for Pediatric Patients With Plaque Psoriasis

Eli Lilly & Co. (LLY) said Saturday that, following positive study results, it plans to seek US regulatory approval for Taltz (ixekizumab), an injectable drug, to be used as treatment for pediatric patients with moderate to severe plaque psoriasis.

The company said that results from its study indicate that Taltz may have the potential to clear skin and reduce itch in pediatric patients with moderate to severe plaque psoriasis.

In the study, a total of 201 patients aged 6 to less than 18 years with moderate to severe plaque psoriasis were randomized to receive Taltz or placebo. In week 12, 89% of patients treated with Taltz achieved 75% improvement on their Psoriasis Area and Severity Index score (PASI 75), compared with 25% of patients treated with placebo. In addition, 81% of patients treated with Taltz achieved a static Physician’s Global Assessment of clear or almost clear skin (sPGA 0,1), compared 11% of patients treated with placebo.

Taltz is currently approved to treat adults with moderate to severe plaque psoriasis and adults with active psoriatic arthritis and active ankylosing spondylitis.

Lilly presented the results of the study at the European Academy of Dermatology and Venereology Congress in Madrid, Spain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*